Aarhus Universitets segl

Peter Hokland

Professor, dr. med., Professor emeritus

Profile photoPeter Hokland
Institut for Klinisk Medicin
Palle Juul-Jensens Boulevard 99
Aarhus N
E-mail: phokland@clin.au.dk
Mobil: +4520225333
Telefon: +4520225333

Peter Hokland, Danish MRC professor in Cancer Therapy, Professor in Hematology,

- 1 page CV, 12/18


1951:             Born (26.09.) in Ebeltoft.

1971:              Baccalaureate, Grenå Gymnasium

1978:              MD, Århus University

1989:              Physician-in-Chief Dept. Hematology, Århus Amtssygehus

2001:              Professor in Cancer Therapy, Danish MRC

2003:              Professor in Hematology, University of Aarhus

2014               Knight, Order of Dannebrog

Scientific degrees and evaluations:

1978:              Students dissertation: Gold medal, Århus University, clinical immunology.

1981:              Doctor Sciences, Aarhus University: "Human peripheral blood lymphocytes. Isolation, subset characterization and in vitro properties. A review of the literature of the 1970's". Published as supplement 277 to Acta Path. Microbiol. Scand. Sect. C 1981.

1988:              Deemed qualified professorship in Theoretical Immunology, Århus University

1997:              Deemed qualified professorship in Hematology, University of Copenhagen

2001:              Danish MRC Professor in Cancer Therapy

2003               Professor in Hematology, University of Aarhus

Scientific affiliations:

1975-78         Surnumerary at the Institute for Med. Microbiology, Århus University

1979               Surnumerary at the Basel Institute for Immunology 

1981-82         Research fellow Dana-Farber Cancer Institute, Division of Tumor Immunology (Prof. Stuart F. Schlossman), Harvard medical School, Boston

1984               One month visit Harvard Medical School 

1987               One month visits to bone marrow transplantation centers in Los Angeles, Boston and  Seattle.

Scientific supervision:

1985               10 medal/diploma reports, 17 Ph.D. reports (7 biol., 10 med.) and 5 D. Sci. dissertations

                         Ongoing supervision; 2 Ph.D. and 3 D. Med. Sci. projects

Scientific evaluations (selected):

1984 -             Opponent on 4 diploma reports, 20 Ph.D.- and 6 D. Sci dissertations at universities in Århus, Odense, Copenhagen and Stockholm

1986  -            Member of Editorial Board, European journal of Haematology

1982   -           Ad hoc referee for > 30 journals including: Blood, Cytometry, Nature Medicine, British Journal of Haematology & Leukemia

1990-              Expert evaluator, EC Biomedicum 1/2 program (”Cell and Molecular Biology”)

1991 -             Evaluator for positions and promotions at the universities in Århus, Odense, Copenhagen, London, Durham and Philadelphia

1994               Member of the Scientific Committee, Danish Cancer Society

2001               Member, Scientific Advisory Committee Novo-Nordisk A/S

2004               Consultant, Novo-Nordisk A/S

2007               Welcome Trust grant evaluator

2008               Member, Cancer Evaluation Committees in Finland, England, France & Portugal

2010               Member, editorial board, British Journal of Haematology

2011               Associate-editor, British Journal of Haematology

2011               Coordinating Professor, The Cancer & Inflammation Center, Aarhus University Hospital

2014               Visiting professor, Siriraj Hospital, Bangkok (ongoing)

2015               Head, Committee on Duplicate Text Screening, HEALTH, AU

2016               Editorials Editor, British Journal of Haematology

2017               Expert advisor, Portuguese research Council

2019               Member of Awards Committee, American Society for Hematology

2019               Member, International Committee, Independent Research Fund Denmark                           

2019               Senior Editor, British Journal of Haematology




Peter Hokland, recent peer-reviewed publications


1.A, 1stauthor

CA, coauthor

SA, senior author

SSA, Shared Senior author


159. Olesen LH, Clausen N, Dimitrijevic A, Kerndrup G, Kjeldsen E, Hokland P. Prospective application of a multiplex reverse transcription-polymerase chain reaction assay for the detection of balanced translocations in leukaemia: a single-laboratory study of 390 paediatric and adult patients. Br J Haematol2004;127(1):59-66. (SA)

160. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol2004;125(5):590-600. (SA)

161. Ostergaard M, Stentoft J, Hokland P. A real-time quantitative RT-PCR assay for monitoring DEK-CAN fusion transcripts arising from translocation t(6;9) in acute myeloid leukemia. Leuk Res2004;28(11):1213-5. (SA)

162. Petersen KB, Hokland P, Petersen GB, Nyvold CG. Erythropoietin receptor defect: a cause of primary polycythaemia. Br J Haematol2004;125(4):537-8. (SA)

163. Abdallah BM, Haack-Sorensen M, Burns JS, et al. Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite [corrected] extensive proliferation. Biochem Biophys Res Commun2005;326(3):527-38. (CA)

164. Andersen CL, Gruszka-Westwood A, Atkinson S, et al. Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization. Cancer Genet Cytogenet2005;156(2):122-8. (CA)

165. Castor A, Nilsson L, Astrand-Grundstrom I, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med2005;11(6):630-7. (CA)

166. Olesen LH, Aggerholm A, Andersen BL, et al. Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling. Br J Haematol2005;131(4):457-67. (SA)

167. Olesen LH, Nyvold CG, Aggerholm A, Norgaard JM, Guldberg P, Hokland P. Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL. Eur J Haematol2005;75(3):185-92. (SA)

168. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol2006;76(1):23-32. (SA)

169. Hasle H, Lund B, Nyvold CG, Hokland P, Ostergaard M. WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder. Leuk Res2006;30(5):543-6. (CA)

170. Khan R, Aggerholm A, Hokland P, Hassan M, Hellstrom-Lindberg E. A pharmacodynamic study of 5-azacytidine in the P39 cell line. Exp Hematol2006;34(1):35-43. (CA)

171. Nyvold CG, Stentoft J, Braendstrup K, et al. Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: Biological and clinical implications. Leukemia2006;20(11):2051-4. (SA)

172. Rethmeier A, Aggerholm A, Olesen LH, et al. Promoter hypermethylation of the retinoic acid receptor beta2 gene is frequent in acute myeloid leukaemia and associated with the presence of CBFbeta-MYH11 fusion transcripts. Br J Haematol2006;133(3):276-83. (SA)

173. Schroeder H, Kamperis K, Grunnet N, Hokland P. Prediction of target CD34 positive cells following leukopheresis in children with neuroblastoma. Pediatr Blood Cancer2006;46(7):786-92. (SA)

174. Stentoft J, Hokland P, Ostergaard M, Hasle H, Nyvold CG. Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res2006;30(4):389-95. (CA)

175. Nyvold CG, Bendix K, Brandsborg M, Pulczynski S, Silkjaer T, Hokland P. Multiplex PCR for the detection of BCL-1/IGH and BCL-2/IGH gene rearrangements--clinical validation in a prospective study of blood and bone marrow in 258 patients with or suspected of non-Hodgkin's lymphoma. Acta Oncol2007;46(1):21-30.(SA)

176. Vangsted A, Gimsing P, Klausen TW, et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation.Int J Cancer2007;120(5):1036-45. (CA)

177. Nyvold CG, Stentoft J, Braendstrup K, Melsvik D, Moestrup SK, Juhl-Christensen C, Hasle H, Hokland P.

                  Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: Biological and clinical implications.

                  Leukemia. 2007 (11):2051-4.  (CA)

178. Kastrup IB, Worm J, Ralfkiaer E, Hokland P, Guldberg P, Grønbæk K.

                  Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma.

                  Eur J Haematol. 2007 80, 61-66 (CA)

179. Grövdal M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Wallvik J, Tangen JM, Oberg G, Jacobsen SE, Hokland P, Porwit A, Hellström-Lindberg E.Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.

                  Clin Cancer Res. 2007 13, 7107-12. (CA)

180. Grønbæk K, Ralfkiaer U, Dahl C, Hother C, Burns JS, Kassem M, Worm J, Ralfkiaer EM, Knudsen LM, Hokland P, Guldberg P.Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms.

                  Mol Pathol. 2008, 1-7 (CA)

181. Ommen HB, Nyvold CG, Brændstrup K, Andersen BL, Ommen IB, Hasle H, Hokland P, Ostergaard M.Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.

                  Br J Haematol. 2008 141, 782-791 (SA)

182. Grubach L, Juhl-Christensen C, Rethmeier A, Olesen LH, Aggerholm A, Hokland P, Ostergaard M.Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. (SA)

                  Eur J Haematol. 2008 Apr 10. (SA)

183. Juhl-Christensen C, Bomberg M, Melsvik D, Hokland P, Nyvold CG.Capillary gel electrophoresis: A simple method for identification of mutations and polymorphisms in the CEBPA gene in patients with acute myeloid leukaemia (AML).

                  Eur J Haematol. 2008 Jun 30.  (SA)

184. Sammalkorpi H, Alhopuro P, Niittymäki I, Orntoft TF, Hokland P, Karhu A, Aaltonen LA.Mutation analysis of MYH11 in acute myeloid leukemia. (CA)

                  Leuk Lymphoma. 2008, 49:1829-31.

185. Ahn EY, Yan M, Malakhova OA, Lo MC, Boyapati A, Ommen HB, Hines R, Hokland P, Zhang DE.Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.

                  Proc Natl Acad Sci U S A. 2008 Oct 24. (CA)

186. Candiloro IL, Mikeska T, Hokland P, Dobrovic A. Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene.

                  Epigenetics Chromatin. 2008 Nov 3;1(1):7.

187. Minimal engraftment of human CD34+ cells mobilized from healthy donors in the infarcted heart of athymic nude rats.

                  Sondergaard CS, Bonde J, Dagnæs-Hansen F, Nielsen JM, Zachar V, Holm M, Hokland P, Pedersen L.

                  Stem Cells Dev. 2008 Nov 7. (CA)

188. Hokland P, Ommen HB, Nyvold CG, Stentoft J, Braendstrup K, Andersen BL, Mikkelsen LS, Ostergaard M.

Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences.        Ugeskr Laeger. 2009 Jan 19;171(4):232-5. (FA)

189. Hokland P, Nyvold CG, Stentoft J, Ommen HB, Ebbesen LH, Braendstrup K, Andersen BL, Mikkelsen LS, Ostergaard M.         Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation. 

                  Ugeskr Laeger. 2009 Jan 19;171(4):229-31. (FA)

190. Zangenberg M, Grubach L, Aggerholm A, Silkjaer T, Juhl-Christensen C, Nyvold CG, Kjeldsen E, Ommen HB, Hokland P.

The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML.

                  Eur J Haematol. 2009 83, 439-48 (SA)

* 191. Ommen HB, Schnittger S, Jovanovic JV, Ommen IB, Hasle H, Østergaard M, Grimwade D, Hokland P.

Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010 Jan 14;115(2):198-205. (SA) (IF 13.2)

192. Ommen HB, Ostergaard M, Yan M, Brændstrup K, Zhang DE, Hokland P.

Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse.

                                    Eur J Haematol. 2010, 84:128-132 (SA)

193. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D. miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts.

Cell. 2010 Mar 5;140(5):652-665. (CA)

194. Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM,Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. 

Br J Haematol. 2010 Aug;150(3):293-302. (CA)

195. Hokland P & Beier Ommen H: Towards individualized follow-up in adult acute myeloid leukemia in remission: what is lacking before we can apply minimal residual disease as an integrated tool in clinical decision-making?

                  Blood March 3, 117, 2577-2584, 2011 (1stA)

196. Petersen CC, Nederby L, Roug AS, Skovbo A, Peterslund NA, Hokland P, Nielsen B, Hokland M.

Increased Expression of CD69 on T Cells as an Early Immune Marker for Human Cytomegalovirus Reactivation in Chronic Lymphocytic Leukemia Patients.

Viral Immunol. 2011 Apr;24(2):165-9. (CA)

* 197. Mette Østergaard, Charlotte Guldborg Nyvold, Jelena Jovanovic, MortenTolstrup Andersen, Veli Kairisto, Yvonne Morgan, Khalid Tobal, Niels Pallisgaard, Ugur Özbek, Heike Pfeifer, Susanne Schnittger, Lykke Grubach, Jan Kaare Larsen1, David Grimwade, and Peter Hokland.”Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet (ELN)” Leukemia, 2011 1168-73. (SA) (IF 11.7)

198. Roug AS, Nyvold CG, Juhl-Christensen C, Christensen M, Schnittger S, Hokland P. A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.

Eur J Haematol. 201; 87, 461-463. (SA)

199. Østergaard Larsen H, Roug AS, Søndergaard CS, Hokland P. Non-viral transfection of leukemic primary cells and cell lines by siRNA – a direct comparison between Nucleofection and Accell delivery. Experimental Hematology, 2011; 39, 1081-1089 (SA)

200. Roug AS, Østergaard Larsen H, Møller HB, Just T, Brown GD, Hokland P. Expression of the hMICL in Acute Myeloid Leukemia - a reliable marker for disease at diagnosis and during follow-up. Clinical Flow Cytometry, 2012; 82, 3-8 (SA)

201. Tan AY, Wong SQ, Nyvold CG, Carney DA, Wei A, Seymour JF, Hokland P, Westerman DA, Dobrovic A.

Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting (HRM) analysis.

Leuk Lymphoma.2012 Jun;53(6):1225-9. doi: 10.3109/10428194.2011.645817. Epub 2012 Jan 13. (CA)

202. Juhl-Christensen C, Ommen HB, Aggerholm A, Lausen B, Kjeldsen E, Hasle H, et al. Genetic and epigenetic events in childhood AML –- similarities and differences with adult AML. Pediatric Oncology, 58, 525-31 2012 (SA)

203. Ommen, HB, Roug AS & Hokland, P: The minimal residual disease concept coming of age – now for the direct comparison between methodologies. Editoral. Leuk Res  36, 392-93 2012(SA)

204. Hamborg KH, Bentzen HH, Grubach L, Hokland P, Nyvold CG.

                  A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma.

Eur J Haematol. 2012 Jul 24. doi: 10.1111/j.1600-0609.2012.01837.x. [Epub ahead of print] 

205. Lo MC, Peterson LF, Yan M, Cong X, Jin F, Shia WJ, Matsuura S, Ahn EY, Komeno Y, Ly M, Ommen HB, Chen IM, Hokland P, Willman CL, Ren B, Zhang DE.

Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML.

Blood. 2012 Aug 16;120(7):1473-84. Epub 2012 Jun 26.

* 206. Hokland P, Ommen HB, Nyvold CG, Roug AS.

                  Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission - methodologies in relation to their clinical situation.

Br J Haematol. 2012 Sep;158(5):569-80. (IF 5.6)

207. Kämpjärvi K, Mäkinen N, Kilpivaara O, Arola J, Heinonen HR, Böhm J, Abdel-Wahab O, Lehtonen HJ, Pelttari LM, Mehine M, Schrewe H, Nevanlinna H, Levine RL, Hokland P, Böhling T, Mecklin JP, Bützow R, Aaltonen LA, Vahteristo P. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.

Br J Cancer. 2012 Nov 6;107(10):1761-5. 2012 Sep 20.

208. Silkjaer T, Nørgaard JM, Aggerholm A, Ebbesen LH, Kjeldsen E, Hokland P, Nyvold CG.

Characterization and prognostic significance of mitochondrial DNA variations in acute myeloid leukemia.

Eur J Haematol. 2013 May;90(5):385-96. doi: 10.1111/ejh.12090. Epub 2013 Mar 22.

209. van Kooten Niekerk PB, Roug AS, Petersen CC, Ommen HB, Kjeldsen E, Bendix K, Nyvold CG, Nederby L, Hokland P.

Chronic myeloid leukaemia presenting with isolated thrombocythaemia, a case revealing its stem cell biology.

Br J Haematol. 2013 Apr 18. doi: 10.1111/bjh.12339.

210. Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ, Walker CJ, Hokland P, Roy DC, Caligiuri MA, Marcucci G, Huettner CS, Perrotti D.

                  Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.

Leukemia. 2013 May 14. doi: 10.1038/leu.2013.151. 

211. Hokland P, Cotter F.

Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way.

Br J Haematol. 2013 Aug;162(4):429-30. doi: 10.1111/bjh.12419. Epub 2013 Jun 15. 

212. Silkjaer T, Nyvold CG, Juhl-Christensen C, Hokland P, Nørgaard JM.

Mitochondrial cytochrome c oxidase subunit II variations predict adverse prognosis in cytogenetically normal acute myeloid leukaemia.

Eur J Haematol. 2013 Jul 4. doi: 10.1111/ejh.12166. [Epub ahead of print]

213. Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti D.

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

Blood. 2013 Aug 22. [Epub ahead of print]

* 214. Torgersen ML, Engedal N, Bøe SO, Hokland P, Simonsen A.

Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells.

Blood. 2013 Aug 22. [Epub ahead of print]

PMID: 23970379 [PubMed - as supplied by publisher] (IF 13.2)

215. Mogensen TH, Bernth-Jensen JM, Gadegaard KH, Petersen M, Petersen CC, Nyvold CG, Hokland M, Hokland P, Larsen CS

Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab?

BMC Blood disorders 2013

216. Herborg, LL, Nederby L, Kjeldsen K, Grønbæk K, Hokland P, Hansen M, Hansen MC, Roug AS

Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm

Leukemia Research Reports, 2, 51-53, 2013

217. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

J Clin Invest. 2013 Sep 3. doi:pii: 68951. 10.1172/JCI68951. (IF 12.7)

218. Roug AS, Hokland LB, Segel E, Nielsen K, Toft-Petersen M, Van Kooten Niekerk PB, Hokland P, Nederby L.

Unraveling stem cell and progenitor subsets in autologous grafts according to methods of mobilization: implications for prediction of hematopoietic recovery.

Cytotherapy. 2014 Mar;16(3):392-401

* 219. Roug AS, Larsen HØ, Nederby L, Just T, Brown G, Nyvold CG, Ommen HB, Hokland P.

hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.

Br J Haematol. 2014 Jan;164(2):212-22 (IF 5.6)

220. Hokland P, Cotter F.

Publishing data from failed cytogenetic assays- what can we learn?

Br J Haematol. 2014 Jan;164(2):163-4.

221. Peter B. van Kooten Niekerk, Charlotte C. Petersen, Charlotte G. Nyvold, Hans B. Ommen, Anne S. Roug, Line Nederby, Peter Hoklandand Eigil Kjeldsen (SSA)

Cell sorting enables interphase fluorescence in situhybridization detection of low BCR-ABL1producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission

Br J Haematol 164, January 2014, 53–60

222. Hans Beier Ommen, Peter Hokland, Torsten Haferlach, Lotte Abildgaard, Tamara Alpermann, Claudia Haferlach, Wolfgang Kern, and Susanne Schnittger. 

Relapse kinetics in acute myeloid leukaemias with MLLtranslocations or partial tandem duplications within the MLLgene. 

Br J Haematol, 2014 Jun;165(5):618-28. 

223. Hokland P.

Janet Rowley 1925-2013: a rock star of haematology and genetics.

Br J Haematol. 2014 May;165(3):269-70.

224. Jeyaratnam DC, Baduin BS, Hansen MC, Hansen M, Jørgensen JM, Aggerholm A, Ommen HB, Hokland P, Nyvold CG

Delineation of known and new transcript variants of the SETMAR (Metnase) gene and the expression profile in hematologic neoplasms.

Exp Hematol. 2014 Jun;42(6):448-56.

225. Sørensen CD, Jørgensen JM, Nederby L, Hokland P, Nyvold CG.

Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.

J Immunol Methods. 2014 Apr;406:131-6.

* 226. Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P, Hokland P, Holm MS, Cazzola M, Malcovati L, Tauro S, Bowen D, Boultwood J, Pellagatti A, Pimanda JE, Unnikrishnan A, Vyas P, Göhring G, Schlegelberger B, Tobiasson M, Kvalheim G, Constantinescu SN, Nerlov C, Nilsson L, Campbell PJ, Sandberg R, Papaemmanuil E, Hellström-Lindberg E, Linnarsson S, Jacobsen SE.

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Cancer Cell. 2014 Jun 16;25(6):794-808. (IF 27.5)

227. Roug AS, Hansen MC, Nederby L, Hokland P.

Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.

Br J Haematol. 2014 Aug 7. doi: 10.1111/bjh.13048. [Epub ahead of print]

228. Toft-Petersen M, Kjeldsen E, Nederby L, Grønbæk K, Hokland P, Roug AS.

A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia.SSA

Leuk Res Rep. 2014 Nov 13;3(2):94-7. doi: 10.1016/j.lrr.2014.09.002. eCollection 2014.

* 229. Pløen GG, Nederby L, Guldberg P, Hansen M, Ebbesen LH, Jensen UB, Hokland P, Aggerholm A.

Persistence of DNMT3A mutations at long-term remission in adult patients with AML.SSA

Br J Haematol. 2014 Nov;167(4):478-86. doi: 10.1111/bjh.13062. Epub 2014 Aug 4. )IF 5.6)

230. OmmenHB, Touzart A, MacIntyre E, Kern W, Haferlach T, Haferlach C, Tobal K, HoklandP, Schnittger S.

The kinetics of relapse in DEK-NUP214 positive acute myeloid leukemia patients.

Eur J Haematol. 2015 Jan 21. doi: 10.1111/ejh.12511. [Epub ahead of print]

231. Hansen MC, Nyvold CG, Roug AS, Kjeldsen E, Villesen P, Nederby L, Hokland P.

Nature and nurture: a case of transcending haematological pre-malignancies in a pair of monozygotic twins adding possible clues on the pathogenesis of B-cell proliferations.

Br J Haematol. 2015 May;169(3):391-400. doi: 10.1111/bjh.13305. Epub 2015 Mar 5.

232.Hokland P,Cotter F.

Real world data on acute myeloid leukaemia therapy from the developing world - an eye-opener.

Br J Haematol. 2015 Apr 8. doi: 10.1111/bjh.13410. [Epub ahead of print] No abstract available.

233. Hokland P, Ommen HB, Mulé MP, Hourigan CS.

Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.

Semin Hematol. 2015 Jul;52(3):184-92. 

234. Hansen MC, Nederby L, Roug A, Villesen P, Kjeldsen E, Nyvold CG, Hokland P.

Novel scripts for improved annotation and selection of variants from whole exome sequencing in cancer research.

MethodsX. 2015 Mar 12;2:145-53. doi: 10.1016/j.mex.2015.03.003.

235. Kämpjärvi K, Kim NH, Keskitalo S, Clark AD, von Nandelstadh P, Turunen M, Heikkinen T, Park MJ, Mäkinen N, Kivinummi K, Lintula S, Hotakainen K, Nevanlinna H, Hokland P, Böhling T, Bützow R, Böhm J, Mecklin JP, Järvinen H, Kontro M, Visakorpi T, Taipale J, Varjosalo M, Boyer TG, Vahteristo P.

Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.

Prostate. 2015 Sep 18. doi: 10.1002/pros.23092. 

236. Chotirat S, Suriyo T, Hokland M, Hokland P, Satayavivad J, Auewarakul CU. Cholinergic activation enhances retinoic acid-induced differentiation in the human NB-4 acute promyelocytic leukemia cell line.

Blood Cells Mol Dis. 2016 Jul; 59:77-84..

* 237. Toft-Petersen M, Nederby L, Kjeldsen E, Kerndrup GB, Brown GD, Hokland P, Stidsholt Roug A.

Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome.

Br J Haematol. 2016 Sep 9. doi: 10.1111/bjh.14270. SSA (IF 5.6)

* 238. Hokland P, Cotter FE, Hansen MC.

Can exome scans be expected to be part of real-time decision-making in patients with haematological cancers?

Br J Haematol. 2016 Aug;174(3):486-92. doi: 10.1111/bjh.14183. Epub 2016 Jun 28. (IF 5.6)

239. Hokland P, Cotter F.

Honest reporting and elucidation of very serious adverse events: a lesson to us all.

Br J Haematol. 2016 Aug;174(3):341-2. doi: 10.1111/bjh.14159. Epub 2016 Jun 24. No abstract available.

240.  Hansen MC, Herborg LL, Hansen M, Roug AS, Hokland P.

Combination of RNA- and exome sequencing: Increasing specificity for identification of somatic point mutations and indels in acute leukaemia.

Leuk Res. 2016 Oct 21;51:27-31. doi: 10.1016/j.leukres.2016.10.009. [Epub ahead of print]

PMID: 27821287

241. Appe AJ, Aggerholm A, Hansen MC, Ebbesen LH, Hokland P, Bentzen HH, Nyvold CG.

                  Differential expression levels and methylation status of ROBO1 in mantle cell lymphoma and chronic lymphocytic leukaemia.

                  Int J Lab Hematol. 2016 Dec 22. 

* 242. Hourigan CS, Haferlach T, Hokland P.

                  Cord-Blood Transplantation in Patients with Minimal Residual Disease.

                  N Engl J Med. 2016 Dec 1;375(22):2204. (IF 16.7)

243. Hokland P, Hokland M.

A clearer light on the role of NK cells in haematological malignancies.

Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14867. [Epub ahead of print]

244. Bill M, B van Kooten Niekerk P, S Woll P, Laine Herborg L, Stidsholt Roug A, Hokland P, Nederby L. (SSA)

Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology.

J Cell Mol Med. 2018 Feb 7. doi: 10.1111/jcmm.13519. [Epub ahead of print]

245. Svenningsen M, Herborg LL, Hokland P, Ludvigsen M.

Monoclonal B-cell lymphocytosis; not the same as B-cell chronic lymphocytic leukaemia.

246. Hansen MC, Nederby L, Kjeldsen E, Petersen MA, Ommen HB, Hokland P.

                  Case report: Exome sequencing identifies T-ALL with myeloid features as a IKZF1-struck early precursor T-cell malignancy.

Leuk Res Rep. 2017 Nov 15;9:1-4. doi: 10.1016/j.lrr.2017.11.002. eCollection 2018

247. Sørensen CD, Møller BK, Olesen G, Hokland P, Hokland M.

Complete donor chimerism following 0/10 HLA-mismatched unrelated donor allogeneic hematopoietic stem cell transplantation.

Bone Marrow Transplant. 2018 Jun 8. doi: 10.1038/s41409-018-0229-y. [Epub ahead of print] 

248. Hokland P, Hansen MC.

                  Acute myeloid/T-lymphoblastic leukaemia (ATML) - a disease entity to look out for.

Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15429.

249. Simonsen AT, Hansen MC, Kjeldsen E, Møller PL, Hindkjær JJ, Hokland P, Aggerholm A. (SSA)

Systematic evaluation of signal-to-noise ratio in variant detection from single cell genome multiple displacement amplification and exome sequencing.

BMC Genomics. 2018 Sep 17;19(1):681. doi: 10.1186/s12864-018-5063-5.

250. Hokland P, Hokland M, Cotter F.

                  The Nobel Prize for Medicine awarded for cancer therapy by inhibition of negative immune regulation.

Br J Haematol. 2018 Dec;183(5):698-700. doi: 10.1111/bjh.15694. 

251. Bill M, Aggerholm A, Kjeldsen E, Roug AS, Hokland P, Nederby L. (SSA)

Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy.

Br J Haematol. 2018 Dec 5. doi: 10.1111/bjh.15711.